Galapagos
is a drug discovery company with two operating divisions: drug
discovery and BioFocus DPI, Galapagos’ service division.
Galapagos’ drug discovery division aims to develop novel,
disease-modifying drugs in selected bone and joint disease areas
for which there is a need for safe and effective medicines.
Galapagos’ BioFocus DPI service division offers a full
suite of target-to-candidate drug discovery products and services
to pharmaceutical and biotech companies as well as to not-for-profit
organizations, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates.
August 26, 2008 Galapagos
acquires structure-based drug discovery from Sareum
Read more